Call to Action for Cancer Care Improvement Act

Representatives Lois Capps and Charles Boustany have introduced the Comprehensive Cancer Care Improvement Act (H.R. 1844), which would improve care for lymphoma patients by encouraging comprehensive cancer care planning from the point of diagnosis through primary treatment and into survivorship. Remember: legislators will not support the bill unless they hear from you!

The Lymphoma Research Foundation (LRF) encourages every member of the lymphoma community to contact their U.S. Representative and urge them to co-sponsor this important legislation. Call your Representative, and using the talking points below, tell them we need their support! You may reach your Representative via the Capitol Switchboard at (202) 224-3121. Ask the operator to transfer you to your Representative's office.

Talking Points For Phone Calls To U.S. Representatives

  • • Tell staff you are calling to urge your Representative to co-sponsor the Comprehensive Cancer Care Improvement Act, H.R. 1844.
  • • The bill would encourage heath care providers to: 1) develop a written cancer care plan for patients and 2) review the details of the plan with their patients before treatment begins and then again at the conclusion of their treatment.
  • • The bill would also allow Medicare to reimburse physicians for the time required to develop and communicate these plans to patients, an important consideration as the majority of U.S cancer patients are beneficiaries of that program.
  • • Add any personal connection to lymphoma that you wish to share and/ or why this legislation would help you, your family, or someone you know whose life has been affected by lymphoma.
  • • Ask your Representative to co-sponsor the Comprehensive Cancer Care Improvement Act by contacting the offices of Representatives Lois Capps or Charles Boustany.
  • • Remember to leave your name and address, so that your Representative can follow-up and inform you whether he or she co-sponsored the bill.
Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap